

# PDL and Benefit Plan updates - July 1, 2010

## Fully Insured customers on the Advantage PDL



The July 1, 2010 PDL changes represent a small percentage of all prescriptions – **no medications in the top 50** – but create significant value for our customers. These decisions are designed to drive the greatest total health care value, while preserving affordable choice for members, with the least amount of disruption.

**For a general list of all impacted medications and member communication materials or for more detailed rationale, please visit Employer eServices or contact your UnitedHealthcare Representative. Please see the “Decision Definitions Key” included at the end of this document for symbol indications.**

Decisions	Assessment	Effective Date
<b>Therapeutic Class Overviews</b>		
<b>Ulcers, Heartburn, and Reflux (Proton Pump Inhibitors - PPIs)</b>		
<ul style="list-style-type: none"> <li> Aciphex®, Protonix®, Zegerid®</li> <li> pantoprazole (generic Protonix) - 04/07 Rider</li> <li> Kapidex™</li> </ul>	<p>With <b>multiple over-the-counter (OTC) options</b> available including Prilosec, recently launched Prevacid 24HR, and soon-to-launch Zegerid, an evaluation of the therapeutic class was necessary. All PPIs are therapeutically equivalent and clinically similar to one another.</p> <ul style="list-style-type: none"> <li>• Aciphex, Protonix, and Zegerid are <b>over seven times more expensive</b> than generic Prilosec and no longer warrant a Tier 2 placement.</li> <li>• Generic Protonix continues to be priced at a premium to the brand. It is <b>over five times more</b> than OTC options and <b>eight times more</b> than generic Prilosec.</li> <li>• Kapidex, currently excluded at launch, will now provide another Tier 3 option.</li> </ul>	7/1/10
<b>High Cholesterol</b>		
<ul style="list-style-type: none"> <li> Vytorin®</li> <li> Zetia®</li> </ul>	<p>In a crowded therapeutic class, with several lower cost alternatives including simvastatin (generic Zocor in Tier 1), Crestor (Tier 2), and Lipitor (Tier 2), <b>Vytorin and Zetia do not offer additional value.</b></p> <ul style="list-style-type: none"> <li>• Vytorin, comprised of Zetia and simvastatin, is <b>priced at a premium.</b></li> <li>• Zetia <b>costs 10 times more</b> than simvastatin yet does not lower cholesterol levels as effectively.</li> </ul>	7/1/10
<b>Acne</b>		
<ul style="list-style-type: none"> <li> Tazorac® cream and gel</li> <li> Neobenz® Micro / SD, Triaz® Foaming Cloth</li> <li> Ziana®</li> </ul>	<p><b>The acne therapeutic class is crowded with little innovation and several OTC options.</b></p> <ul style="list-style-type: none"> <li>• Tazorac cream and gel are approximately <b>three times more expensive</b> than tretinoin in Tier 1.</li> <li>• Both the Neobenz Micro products and Triaz Foaming Cloth are currently excluded at launch and are <b>11 to 17 times more expensive</b> than OTC benzoyl peroxide products.</li> <li>• Ziana is <b>four times more expensive</b> than its individual components which are both in Tier 1.</li> </ul>	7/1/10
<b>Excessive Daytime Drowsiness</b>		
<ul style="list-style-type: none"> <li> Nuvigil®</li> <li> Provigil® - 07 Rider</li> </ul>	<p><b>Recently launched Nuvigil is less expensive than therapeutically equivalent Provigil.</b></p> <ul style="list-style-type: none"> <li>• Prior to Nuvigil's launch, the price of Provigil increased significantly - <b>approximately 40% within 18 months</b> and <b>currently cost about 50% more</b> than Nuvigil. Given generic Provigil is expected to launch in 2012, the price of Provigil is likely to continue to increase.</li> <li>• Nuvigil, currently excluded at launch, <b>will now provide a lower cost option.</b></li> </ul>	7/1/10 or earlier
<b>Select Designated Pharmacy Program</b>		
<ul style="list-style-type: none"> <li> <b>Diabetes:</b> Humalog® / Humalog Mix</li> <li> <b>High Cholesterol:</b> Zetia (see above)</li> </ul>	<p>Humalog products continue to be an expensive Tier 3 option. With Novolin, Novolog, and Novolog Mix available in Tier 1, Humalog products do not offer any additional health care value.</p>	7/1/10

Decisions	Assessment	Effective Date
<b>Down-Tiers</b>		
2 ▶ 1 <b>acarbose</b> (generic Precose® - diabetes)	These medications have been down-tiered since our last PDL communications. Down-tier decisions are immediately implemented so members can take advantage of the cost savings.	1/25/10
3 ▶ 2 <b>clindamycin / benzoyl peroxide</b> (generic Benzacilin® - acne)		1/25/10
2 ▶ 1 <b>divalproex sodium ER</b> (generic Depakote® ER - seizure disorders)		11/23/09
2 ▶ 1 <b>ketorolac tromethamine</b> (generic Acular® - eye inflammation)		1/25/10
3 ▶ 2 <b>nateglinide</b> (generic Starlix® - diabetes)		1/25/10
3 ▶ 2 <b>Nutropin AQ NuSpin®</b> (growth hormone)		1/12/10
3 ▶ 2 <b>Opana® ER</b> (pain)		1/30/10
3 ▶ 2 <b>Somatuline Depot®</b> (excess growth hormone)		12/2/09
<b>Up-Tiers</b>		
2 ▶ 3 <b>Aciphex</b> (ulcers, heartburn, and reflux)	With <b>multiple OTC options and generic Prilosec in tier 1</b> , Aciphex's overall clinical value no longer warrants a Tier 2 placement.	7/1/10
2 ▶ 3 <b>Dipentum®</b> (inflammatory bowel disease)	Dipentum's overall health care value has decreased. <b>Several Tier 1 and Tier 2 options available.</b>	7/1/10
2 ▶ 3 <b>Protonix</b> (ulcers, heartburn, and reflux)	<b>Over seven times more expensive than generic Prilosec</b> , Protonix does not provide sufficient health care value to remain in Tier 2.	7/1/10
2 ▶ 3 <b>Vytorin</b> (high cholesterol)	Therapeutically equivalent to its individual components, Zetia (Tier 3) and simvastatin (Tier 1), Vytorin is <b>priced at a premium</b> . Crestor and Lipitor are available in Tier 2.	7/1/10
2 ▶ 3 <b>Tazorac cream and gel</b> (acne)	Tazorac cream and gel are <b>approximately three times more expensive</b> than tretinoin in Tier 1.	7/1/10
2 ▶ 3 <b>Zegerid</b> (ulcers, heartburn, and reflux)	<b>Expected to go OTC this year</b> , Zegerid no longer warrants a Tier 2 placement.	7/1/10
<b>Exclusions*</b>		
❌ <b>Aplenzin™</b> (antidepressant) - 07 Rider	Aplenzin, initially excluded at launch, is <b>over four and half times more expensive</b> than therapeutically equivalent, Tier 2 generic Wellbutrin XL.	7/1/10
❌ <b>Edluar™</b> (insomnia) - 07 Rider	Therapeutically equivalent to generic Ambien in Tier 1 and currently excluded at launch, Edluar contains the same active ingredient, zolpidem, yet is <b>13 times more expensive</b> .	7/1/10
❌ <b>Lamictal® ODT™ and Lamictal XR</b> (seizure disorders) - 07 Rider	Lamictal ODT and Lamictal XR, both previously excluded at launch, <b>cost hundreds of dollars more</b> than therapeutically equivalent generic Lamictal in Tier 1. Brand Lamictal is available in Tier 3.	7/1/10
❌ <b>Neobenz Micro / Neobenz Micro SD</b> (acne) - 04/07 Rider	Neobenz Micro products, initially excluded at launch, <b>cost 11 to 17 times more</b> than OTC products all of which contain the same active ingredient, benzoyl peroxide.	7/1/10
❌ <b>Pantoprazole</b> (ulcers, heartburn, & reflux) - 04/07 Rider	Generic Protonix continues to remain expensive since its launch in January 2008, <b>costing five times more</b> than OTC products and <b>eight times more</b> than generic Prilosec.	7/1/10
❌ <b>Provigil</b> (excessive daytime drowsiness) - 07 Rider	Provigil's price has increased significantly - <b>approximately 40% within 18 months</b> , offering less overall health care value than therapeutically equivalent Nuvigil in Tier 3.	7/1/10
❌ <b>Ryzolt™</b> (chronic pain) - 07 Rider	Ryzolt is currently excluded at launch and is <b>20 times more expensive</b> than therapeutically equivalent generic Ultram in Tier 1. Generic Ultram ER is available in Tier 3.	7/1/10
❌ <b>Triaz Foaming Cloth</b> (acne) - 04/07 Rider	A benzoyl peroxide product initially excluded at launch, Triaz Foaming Cloth <b>offers no significant health care value</b> above OTC benzoyl peroxide products and is <b>13 times more expensive</b> .	7/1/10
❌ <b>Ziana</b> (acne) - 07 Rider	Combination product Ziana is <b>four times more</b> than its individual components, antibiotic and retinoid gel which are both in Tier 1.	7/1/10

Decisions		Assessment	Effective Date
<b>New Tier Placements</b>			
<b>2</b>	<b>Gelnique™</b> (overactive bladder)	These medications are currently or were previously excluded at launch and will now be covered under the pharmacy benefit since they offer sufficient value compared to alternatives in their therapeutic class.	1/30/10
<b>3</b>	<b>Kapidex</b> (ulcers, heartburn, and reflux - see above)		7/1/10
<b>3</b>	<b>Nuvigil</b> (excessive daytime drowsiness - see above)		5/1/10 or earlier
<b>Multiple Copay - 07 Rider</b>			
<b>MC</b>	<b>Vusion*</b> (diaper rash)	Typically only a one-time use product, Vusion is <b>priced over \$200 more</b> than OTC options.	7/1/10
<b>Notification</b>			
<b>N</b>	<b>13 Oral Oncology Medications:</b> Afinitor, Gleevec, Hycamtin, Nexavar, Revlimid, Sprycel, Sutent, Tarceva, Tasigna, Temodar, Thalomid, Tykerb, and Votrient.	Notification will be applied to several high-cost, oral oncology medications to ensure coverage is aligned with nationally recognized oncology guidelines. <b>Current users will be grandfathered and will not be impacted.</b>	9/1/10

\*2004 Rider exclusions are based on availability of over-the-counter (OTC) therapeutic equivalents. 2007 Rider exclusions are based on whether the medication contains an active ingredient available in and therapeutically equivalent to another covered drug or a medication that contains an active ingredient which is a modified version of and therapeutically equivalent to another covered medication.

**Please Note:** Multiple Copay and some exclusions may only be implemented for customers on the 2007 Pharmacy Rider. For customers not on the 2007 Pharmacy Rider, exclusions based on the 2007 Rider and Multiple Copay will be not implemented until customer's renewal of the new pharmacy rider and as allowed by state regulation.

## Decision definitions key

Key	Decision	Definition
<b>2 &gt; 1</b>	<b>Down-tiers</b>	Down-tiers refer to medications that move to a lower tier, which can occur at any time throughout the year to provide members with immediate cost savings.
<b>2 &gt; 3</b>	<b>Up-tiers</b>	Up-tiers refer to medications that move to a higher tier because they offer less health care value (either clinically and/or financially) than similar medications in their therapeutic classes.
<b>2</b>	<b>New Tier Placements</b>	New tier placements occur for medications that have been previously excluded at launch, but now offer sufficient health care value to have a tier placement.
<b>DP</b>	<b>Select Designated Pharmacy</b>	The Designated Pharmacy Program is a 2004/2007 Rider capability that steers members to their most cost effective option. This program will encourage members to make better decisions for lower cost medications and/or channel options.
<b>X</b>	<b>Exclusions</b>	We do not make the decision to exclude medications from benefit coverage lightly. A medication is only excluded from benefit coverage when it offers no clinical value over other options in its class and its exclusion can be leveraged to achieve significant savings for our customers and preserve affordable choices for members.
<b>X</b>	<b>Continued Exclusions</b> (previously excluded at launch)	These exclusions will have little to no member impact since the medication has been excluded at launch.
<b>MC</b>	<b>Multiple Copay</b>	We consider Multiple Copay when a medication's packaging is large enough to contain two or more month's worth of product. Members who fill a prescription for the select medication will be charged an additional copayment.
<b>N</b>	<b>Notification</b>	Notification requires physicians provide additional clinical information to verify member benefit coverage and ensure appropriate use based on predefined criteria.
<b>SL</b>	<b>Supply Limits</b>	Supply Limits establish the maximum quantity of drug that is covered per copay or in a specified timeframe.